Lao People's Democratic Republic vs Saudi Arabia: Percentage of bloodstream infection due to Escherichia coli resistant
Lao People's Democratic Republic
52.6%
in 2022
Saudi Arabia
52.8%
in 2022
Lao People's Democratic Republic rank
17th
Saudi Arabia rank
16th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Lao People's Democratic Republic
- Saudi Arabia
How they compare
Saudi Arabia currently reports 52.8% against 52.6% in Lao People's Democratic Republic, a difference of 0.2%.
Across all 6 years both countries report, Saudi Arabia has been ahead every year.
Lao People's Democratic Republic ranks 17th and Saudi Arabia ranks 16th of 50 countries.
Saudi Arabia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lao People's Democratic Republic | Saudi Arabia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 46.9% | 54.3% | 7.4% | Saudi Arabia |
| 2020s | 49.7% | 54.7% | 5.0% | Saudi Arabia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Lao People's Democratic Republic or Saudi Arabia?
- Saudi Arabia, at 52.8% against 52.6% in Lao People's Democratic Republic as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Lao People's Democratic Republic and Saudi Arabia?
- 0.2%, with Saudi Arabia ahead.
- How many years of comparable data are there for Lao People's Democratic Republic and Saudi Arabia?
- 6 years are reported by both, from 2017 to 2022.
- How do Lao People's Democratic Republic and Saudi Arabia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Lao People's Democratic Republic ranks 17th and Saudi Arabia ranks 16th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.